CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Galsulfase (Drug Plan Submission)

Last Updated: April 27, 2015
Result type: Reports
Project Number: SR0434-000
Product Line: Reimbursement Review

Generic Name: Galsulfase (Drug Plan Submission)

Brand Name: Naglazyme

Manufacturer: BioMarin Pharmaceutical (Canada) Inc.

Therapeutic Area: Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)

Indications: Mucopolysaccharidosis VI

Submission Type: Drug Plan Initiated

Project Status: Complete

Date Recommendation Issued: February 19, 2016

Recommendation Type: List with clinical criteria and/or conditions